Focused On-demand Library for Secreted Ly-6/uPAR domain-containing protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Secreted LY6/PLAUR domain-containing protein 2; Secreted Ly-6/uPAR-related protein 2

Alternative UPACC:

P0DP57; D3DWI7; G3XAC2; Q86SR0; Q9BZG9


Secreted Ly-6/uPAR domain-containing protein 2, also known as Secreted LY6/PLAUR domain-containing protein 2 or Secreted Ly-6/uPAR-related protein 2, plays a crucial role in modulating the functional properties of nicotinic and muscarinic acetylcholine receptors. It is involved in regulating keratinocytes proliferation, differentiation, and apoptosis, showcasing its multifaceted role in cellular processes.

Therapeutic significance:

Understanding the role of Secreted Ly-6/uPAR domain-containing protein 2 could open doors to potential therapeutic strategies, particularly in modulating acetylcholine receptor activities for conditions related to keratinocyte dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.